Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Can-Fite BioPharma Ltd., a clinical-stage biotechnology company listed on NYSE American, announced the immediate exercise of outstanding warrants to raise approximately $4 million in gross proceeds by lowering the exercise price from $5.00 to $2.50 per ADS. The funds will support ongoing research, development, and clinical trials of their oncology …